Journals / Optimal Tıp Derg. / 2002 / Cilt: 15 - Sayı: 3

Nitric oxide (NO) and malondialdehyde (MDA) levels in bronchial washing fluid and plasma from patients with lung cancer and pneumonia

Akciğer kanseri ve pnömoni hastalarının bronşial yıkama sıvısı ile plazmalarında nitrik oksit (NO) ve malondialdehit (MDA) düzeyleri

Pages
72–78
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The positive and negative correlations between NO and MDA may show the possible relationships between the parameters studied in both pneumonia and lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this prospective study, malondialdehy de (MDA), an index of the in vivo lipid peroxidation; nitric oxid (NO), a free oxygen radical and an important mediator molecule were studied in bronchial washing fluid (BWF) and plasma from patients with lung cancer (n=13) and pneumonia (n=13).
📊
Key Findings & Data:Control group (n=13) was age- and sex-matched subjects who are following up for certain complaints by the Department of Pulmonary Medicine.
💡
Conclusion & Impact:The positive and negative correlations between NO and MDA may show the possible relationships between the parameters studied in both pneumonia and lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akciğer neoplazmları · Pnömoni · Bronkoalveolar lavaj sıvısı

Abstract

In this prospective study, malondialdehy de (MDA), an index of the in vivo lipid peroxidation; nitric oxid (NO), a free oxygen radical and an important mediator molecule were studied in bronchial washing fluid (BWF) and plasma from patients with lung cancer (n=13) and pneumonia (n=13). Control group (n=13) was age- and sex-matched subjects who are following up for certain complaints by the Department of Pulmonary Medicine. NO and MDA levels were found to be 268.1 ± 46.0 jimol/L, 2.80 ± 0.55 fimol/L, respectively in BWF from patients with lung cancer. On the other hand, plasma concentrations of above-mentioned parameters were found to be 104.7± 34.43 [imol/L, 2.05 + 0.17 \s.mol/L. in pneumonia group; NO levels were found to be 341.6 ± 48.0 fimol/L in BWF and 55.53 ± 9.70 punol/L in plasma; and MDA levels were found to be 3.98 ± 1.09 \>.mol/L in BWF and 2.46 ± 0.24 \imoUL in plasma. When the biochemical analyses were made in control subjects; NO levels were found to be 242.4 ± 24.9 [imol/L in BWF and 61.3 +17.7 fimol/L in plasma; MDA levels were found to-be 4.99± 1.26 [i,mol/L in BWF and 2.59 ± 0.62 fimol/L in plasma. In.a general view there were no statistically significant difference in the parameters studied between the study and control groups. The results were discussed in the light of the literature. The present results have suggested that there were no meaningful relationships between different lung diseases and the levels of nitric oxide and malondialdehy de. The positive and negative correlations between NO and MDA may show the possible relationships between the parameters studied in both pneumonia and lung cancer.

Özet

Bu çalışmada akciğer kanseri (n=13) ve pnömoni (n=13) tanısı konmuş hastaların bronşial yıkama sıvıları ile plazmalarında; lipid per oksidasy onunun bir göstergesi olan malondialdehit (MDA) ve önemli bir mediator, serbest radikal olan nitrik oksit (NO) düzeyleri ölçüldü. Elde edilen sonuçlar kontrol grubunun (n=13) değerleri ile karşılaştırıldı. Akciğer kanseri olan hastaların lavaj sıvılarındaki NO miktarı 268.1 ± 46.0 umol/L, MDA miktarı 2.80 ± 0.55 umol/L, bu grubun plazmalarında ise NO miktarı 104.7 ± 34.43 umol/L, MDA miktarı 2.05 ±0.17 umol/L olarak bulundu. Pnömoni grubundaki hastaların lavaj sıvılarında NO miktarı 341.6 ± 48.0 umol/L, MDA miktarı 3.98 ± 1.09 umol/L olarak ölçüldü. Bu grubun plazmalarında ise NO miktarı 55.53 ± 9.70 umol/L, MDA miktarı ise 2.46 ± 0.24 fnınol/L bulundu. Kontrol grubundaki hastaların lavaj. sıvılarında NO miktarı 242.4 ± 224.9 umol/L, MDA miktarı 4.99 ± 1.26 umol/L, aynı grubun plazmalarında ise NO miktarı 61.3± 17.7 umol/L ve MDA miktarı 2.59 ± 0.62 umol/L bulundu. Akciğer kanserli ve pnömonili hastaların lavaj sıvısı ile plazmalarında yapılan ölçümler arasında anlamlı bir fark tespit edilemedi. Sonuçlar literatürün ışığında tartışıldı. Çalışılan parametrelerde istatistiksel olarak anlamlı fark bulunamaması, akciğer kanseri ve pnömoni hastalıkları ile bu parametreler arasında herhangi ciddi bir sebep-sonuç ilişkisi olmadığını düşündürmektedir. Nitrik oksit ve malondialdehit parametreleri arasında pozitif ve negatif korelasyonların olması bu hastalıklarla çalışılan parametreler arasında bir ilişkinin olabileceğine işaret olabilir.

🔖

Cite This Article

GÖKBULUT, İ., ÖZYURT, H., KÖKSAL, N., YILDIRIM, Z., AKYOL, Ö. (2002). Nitric oxide (NO) and malondialdehyde (MDA) levels in bronchial washing fluid and plasma from patients with lung cancer and pneumonia. Optimal Tıp Derg., Cilt: 15 - Sayı: 3, 72–78. https://ajindex.com/articles/288619

References (14)

  1. Fraser RS, Pare JAP, Frascr RG, Pare PD. (1994) Synopsis of Diseases of the Chest. W.B.Saunders Company; pp: 445-538
  2. Goodhart CB. (1959) Canaer-proneness and lung cancer, Practitioner; 182:574
  3. Johnson DH. Introduction: (1997) Small cell lung cancer in the elderly patiend. Semin Oncol; 24(4): 484-491
  4. Amos CI, Xu W, Spitz MR. (1999) Is there a genetic basis for lung cancer susceptibility? Recent Results Cancer Res;151:3
  5. Johanson WG Jr, Harris GO. (1980) Aspiration pneumonia, anaerobic infections and lung abscess. Med Clin North Am; 64: 385-394
  6. Esterbauer H, Cheeseman K. (1991) Determination of aldehydic lipid peroxidation products: malonaldialdehyde on related aldehydes. Free Radic Biol Med; 11:81-128
  7. Esterbauer H, Zollner H, Schaur RJ. (1988) Hydroxyalkenals: cytotoxic products of lipid peroxidation. ISI Atlas Sci; 1:311-17
  8. Reiter Rj, Acuna-Castroviejo D, Tan DX,Burghardt S. (2001) Free radical- mediated molecular damage: mechanism for the protective actions melatonin in the central nervous system. Ann NY Acad Sci; 939:200-215
  9. Nathan C. (1997) Inducible nitric oxide synthase: What difference does it make? J Clin Invest; 100:2417-23
  10. Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G. (1988) Pharmacological evidence that endothelium derived relaxing factor is nitric oxide: Use of Pyrogallol and SOD to study endothelium-dependent and nitric oxide-elicited vascular smooth mudcle relaxation. J Pharmacol Exp Ther; 244:181-9
  11. Ignarro LJ. (1991) Heme-dependent activation of guanylate cyclase by nitric oxide: a novel signal tranduction mechanism. Blood Vessels; 28:67-73
  12. Pussard G, Gascard JP, Gorenne I, Labat C, ve ark. (1995) Endothelin-I modulates cyclic GMP production and relaxation in human pulmonary vessels. J Pharmacol Exp Ther; 274:969-75.' 13. Wazovicz W, Neve J, Peretz A. (1993) Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: importance of extraction pH and influence of sample preservation and storeage. Clin Chem; 39(12): 2522-2526 14. Ochoa JB, Curti B, Peitzman AB, ve ark. (1992) Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemadynomic changes. J Natl Cancer Inst; 84: 864-867
  13. Cortas NK, Wakid NW. (1990) Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem; 36(8): 1440-1443
  14. Nathan C, Xie Q. Nitric oxide synthases: (1994) Roles, tolls and controls.